Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Advanced Hepatocellular Carcinoma

In brief

The purpose of Phase 1b of the study is to determine the maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PDn) and assess the safety, tolerability and activity of oprozomib in combination with sorafenib in subjects with advanced hepatocellular carcinoma (HCC). The purpose of Phase 2 of the study is to evaluate the efficacy of oprozomib in combination with sorafenib versus sorafenib alone and to compare the key outcome measures for subjects with advanced HCC.

Key facts

Study ID

NCT02227914

Run by

Amgen

People needed

0

Starts

2014-12-01

Expected to finish

2015-03-01

Last updated by the study team

2017-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lahey Hospital & Medical Center — Burlington, California, United States
• Rocky Mountain Cancer Centers — Denver, Colorado, United States
• University of Miami Hospital & Clinics — Miami, Florida, United States
• The University of Chicago Medical Center — Chicago, Illinois, United States
• The Ohio State University, Martha Morehouse Medical Plaza — Columbus, Ohio, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.